ChinaDrugStatus

Datopotamab deruxtecan

德达博妥单抗
Brand: Datroway / 达卓优·Oncology·Last verified 2026-11-20

TROP2-directed ADC newly added to the 2026 NRDL Negotiated List (#288) for previously treated HR+/HER2- unresectable or metastatic breast cancer.

China Approval (NMPA)

Approved
Approval Number(s)
国药准字SJ20250021
Initial Approval Date
Aug 22, 2025
Notice Published
Sep 29, 2026
MAH
Daiichi Sankyo / AstraZeneca (第一三共 / 阿斯利康)
Approved Scope
1 initial presentation(s) & 1 supplemental event(s) verified — see table below.

National Reimbursement

Announced · Effective Jan 1, 2027
2026 Edition Entry
Negotiated #288 · Class B
Agreement Period
2027-01-01 to 2028-12-31
Payment Standard
* Confidential (marked with asterisk in NHSA PDF)
2026 Payment Scope
Restricted to adults with unresectable or metastatic HR-positive, HER2-negative (IHC 0, 1+, or 2+/ISH-) breast cancer after prior endocrine therapy and at least one line of chemotherapy in the advanced setting.
限既往接受过内分泌治疗且在晚期疾病阶段接受过至少一线化疗的不可切除或转移性的激素受体(HR)阳性、人类表皮生长因子受体2(HER2)阴性(IHC 0、IHC 1+或IHC 2+/ISH-)乳腺癌成人患者。

Commercial Insurance List

Not Listed

Not listed in the 2025 or 2026 NHSA Commercial Health Insurance Innovative Drug List.

Approved Products, Dosage Forms & Approval Numbers

2 verified NMPA records
Approval No.Dosage Form & StrengthEvent & ScopeApproval / Notice DateMAH & Source
国药准字SJ20250021
Powder for Injection (注射剂)
100mg/瓶
Supplemental Indication

Supplemental indication for adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are ineligible for PD-1/PD-L1 inhibitor therapy (note: 2026 NRDL covers HR+/HER2- BC only).

适用于不适合接受PD-1/PD-L1抑制剂治疗的不可切除或转移性三阴性乳腺癌(TNBC)成人患者。

Approved: 2026-09-29
Published: 2026-09-29
Daiichi Sankyo / AstraZeneca
国药准字SJ20250021
Powder for Injection (注射剂)
100mg/瓶
Initial Approval

Adult patients with unresectable or metastatic HR-positive, HER2-negative breast cancer after prior endocrine therapy and at least one line of chemotherapy in the advanced setting.

适用于治疗既往接受过内分泌治疗且在晚期疾病阶段接受过至少一线化疗的不可切除或转移性的激素受体(HR)阳性、HER2阴性乳腺癌成人患者。

Approved: 2025-08-22
Published: 2025-08-22
Daiichi Sankyo / AstraZeneca

Change Timeline

  1. (2027-01-01)Basic NRDL· Catalog published: Nov 14, 2026

    2026 NRDL · Added to Negotiated List

    Newly added to 2026 NRDL Negotiated List (#288, Class B, *) for adult HR+/HER2- unresectable or metastatic breast cancer after prior ET and ≥1L chemo.

    Chinese original: 新增纳入2026版谈判药品第288项(乙类,支付标准*),限既往接受过内分泌治疗且晚期经≥1线化疗的HR阳性HER2阴性乳腺癌。

    NHSA · PDF p.148Verified 2026-11-20
  2. (2026-09-29)NMPA Approval

    NMPA Supplemental Indication Approval (国药准字SJ20250021 · 100mg/瓶)

    Supplemental indication for adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are ineligible for PD-1/PD-L1 inhibitor therapy (note: 2026 NRDL covers HR+/HER2- BC only).

    Chinese original: 适用于不适合接受PD-1/PD-L1抑制剂治疗的不可切除或转移性三阴性乳腺癌(TNBC)成人患者。

  3. (2025-08-22)NMPA Approval

    NMPA Initial Marketing Approval (国药准字SJ20250021 · 100mg/瓶)

    Adult patients with unresectable or metastatic HR-positive, HER2-negative breast cancer after prior endocrine therapy and at least one line of chemotherapy in the advanced setting.

    Chinese original: 适用于治疗既往接受过内分泌治疗且在晚期疾病阶段接受过至少一线化疗的不可切除或转移性的激素受体(HR)阳性、HER2阴性乳腺癌成人患者。

Verified Names & Aliases

Every English INN, Chinese generic name, brand name, and R&D code is recorded with its source.

注射用德达博妥单抗dosage name(NHSA)
Dato-DXdcode(WHO)
Datrowaybrand en(WHO)
达卓优brand zh(NMPA)

Primary Sources for This Record